John C Byrd

16PUBLICATIONS
217CO-AUTHORS
Epigenetics (incl. genome methylation and epigenomics)Cancer therapy (excl. chemotherapy and radiation therapy)Solid tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Aug 25, 2026
Epigenetic markers expand genetic risk estimation in acute myeloid leukemia.

|Aug 24, 2026
T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia.

|Jul 28, 2026
OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

|May 20, 2026
RAS Pathway Activation and Microenvironmental Adaptation as Hallmarks of Myeloid Sarcoma.

|Apr 22, 2026
Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib.

|Nov 06, 2025
Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study.

Kerry A Rogers, Pearlly Yan, Ian W Flinn

Pageof 3

Frequent Collaborators

8 joint publications

Jennifer Woyach

4 joint publications

Kerry A Rogers

4 joint publications

Seema A Bhat

4 joint publications

James S Blachly